Rocket One Stock (NASDAQ:HOTH)

Forecast Ownership Financials Chart

Previous Close

$1.33

52W Range

$0.49 - $2.45

50D Avg

$0.80

200D Avg

$1.11

Market Cap

$19.89M

Avg Vol (3M)

$8.12M

Beta

0.58

Div Yield

HOTH Company Profile

Rocket One, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in Hoboken, NJ.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Feb 15, 2019

Website

HOTH Performance

HOTH Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-11.11M	$-8.22M	$-7.69M
Net Income	$-12.47M	$-8.19M	$-7.85M
EBITDA	$-12.36M	$27.13K	$-153.15K
Basic EPS	$-0.90	$-1.28	$-2.30
Diluted EPS	$-0.90	$-1.28	$-2.30

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
DARE	Daré Bioscience, Inc.
ASBP	Aspire Biopharma Holdings, Inc.
PCSA	Processa Pharmaceuticals, Inc.
LEXX	Lexaria Bioscience Corp.
CRIS	Curis, Inc.
BCTX	BriaCell Therapeutics Corp.
PULM	Pulmatrix, Inc.
FBLG	FibroBiologics, Inc. Common Stock
PALI	Palisade Bio, Inc.